Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Exploiting mesoporous silica nanoparticles as versatile drug carriers for several routes of administration

Full text
Author(s):
Sabio, Rafael Miguel [1] ; Meneguin, Andreia Bagliotti [1] ; dos Santos, Aline Martins [1] ; Monteiro, Andreia Sofia [2] ; Chorilli, Marlus [1]
Total Authors: 5
Affiliation:
[1] Sao Paulo State Univ UNESP, Sch Pharmaceut Sci, BR-14800903 Araraquara, SP - Brazil
[2] Sao Paulo State Univ UNESP, Inst Chem, BR-14800060 Araraquara, SP - Brazil
Total Affiliations: 2
Document type: Journal article
Source: Microporous and Mesoporous Materials; v. 312, JAN 2021.
Web of Science Citations: 0
Abstract

The exploitation of mesoporous silica nanoparticles (MSNs) as drug delivery systems has grown exponentially due to their remarkable tunable properties, such as high surface area, chemical and physical stability, high loading and release capacities, distinct possibilities of particle and pore structures, as well as good biocompatibility, biodegradability, and easy clearance. However, the main exposure routes that exploit MSNs qualities, namely intravenous, subcutaneous, intramuscular, intratumoral, ophthalmic, pulmonary, nasal, dermal, and oral administrations, have been underreported to date. In addition, a better understanding of these administration routes can contribute to the development of smart MSNs-based nanoplatforms with interesting properties, such as high stability in physiological media, specificity and efficacy in theranostic applications, and further clinical translations. This review highlights the advantages and challenges of the administration routes aforementioned regarding the MSNs as drug delivery systems. It also shows how their properties can influence the interaction with biological media, and consequently, their biocompatibility, biodistribution, and clearance mostly in pre clinical assays, in order to contribute to further MSNs-based nanoplatform clinical translations. (AU)

FAPESP's process: 18/25377-3 - Potential evaluation of cetuximab-modified mesoporous silica nanoparticles as docetaxel carrier to prostate cancer treatment.
Grantee:Rafael Miguel Sábio
Support Opportunities: Scholarships in Brazil - Post-Doctoral
FAPESP's process: 14/50928-2 - INCT 2014: Pharmaceutical Nanotechnology: a transdisciplinary approach
Grantee:Maria Vitória Lopes Badra Bentley
Support Opportunities: Research Projects - Thematic Grants